



Therapeutic Resolution of Pulmonary Arterial Hypertension

Guest Editor:

Dr. Talat Nasim

School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK

Deadline for manuscript submissions:

31 August 2024

Message from the Guest Editor

Dear Colleagues,

Pulmonary Arterial Hypertension (PAH) is a devastating cardiovascular disorder caused by the narrowing of blood vessels in the lungs and, in the absence of therapy, leads to right heart failure and premature death. The genetic architecture of PAH has been explored over the last twenty years, identifying a number of genes and highlighting the involvement of numerous pathways and risk factors for exploration. There is no cure for this disorder. Current management therapies for PAH are very costly and aim to improve symptoms. Hence, there is a need to identify novel therapeutic interventions.

This Special Issue of BioChem will pay attention to the recent advances in PAH research. Topics include, but are not limited to:

- Molecular genetic basis of PAH
- The role of epigenetics in the pathogenesis of PAH
- Repurposing established drugs for the resolution of PAH
- Therapeutic resolution of PAH using natural products
- Current treatments of PAH and their limitations
- The prospects of biologics for the treatment of PAH
- Resolution of PAH using small molecule agents and gene therapy





Editor-in-Chief

Prof. Dr. Yehia Mechref

Department of Chemistry and
Biochemistry, Texas Tech
University, Lubbock, TX 79409,
USA

Message from the Editor-in-Chief

BioChem is an international and interdisciplinary open access journal encompassing the fields of molecular biology, cell biology, structural biology, nucleic acid biology, chemical biology, synthetic biology, disease biology, biophysics, and theoretical biochemistry. It publishes reviews, research articles, communications, and letters. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 54 days after submission; acceptance to publication is undertaken in 16.5 days (median values for papers published in this journal in the second half of 2023).

Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

Contact Us

BioChem Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biochem
biochem@mdpi.com
[X@BioChem_MDPI](https://twitter.com/BioChem_MDPI)